Aarti Pharmalabs (BOM:543748) Debt-to-Equity : 0.16 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Aarti Pharmalabs Debt-to-Equity?

Aarti Pharmalabs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹2,686 Mil. Aarti Pharmalabs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹167 Mil. Aarti Pharmalabs's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹17,570 Mil. Aarti Pharmalabs's debt to equity for the quarter that ended in Mar. 2024 was 0.16.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Aarti Pharmalabs's Debt-to-Equity or its related term are showing as below:

BOM:543748' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08 Med: 0.15 Max: 0.25
Current: 0.16

During the past 4 years, the highest Debt-to-Equity Ratio of Aarti Pharmalabs was 0.25. The lowest was 0.08. And the median was 0.15.

BOM:543748's Debt-to-Equity is ranked better than
63.18% of 842 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs BOM:543748: 0.16

Aarti Pharmalabs Debt-to-Equity Historical Data

The historical data trend for Aarti Pharmalabs's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aarti Pharmalabs Debt-to-Equity Chart

Aarti Pharmalabs Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

0.08

0.25

0.14

0.16

Aarti Pharmalabs Quarterly Data
	Mar21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial					0.14	N/A	0.13	N/A	0.16

Competitive Comparison of Aarti Pharmalabs's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Pharmalabs's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aarti Pharmalabs's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarti Pharmalabs's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Aarti Pharmalabs's Debt-to-Equity falls into.

Aarti Pharmalabs Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Aarti Pharmalabs's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2685.5	+	167)	/	17570.4
	=	0.16

Aarti Pharmalabs's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2685.5	+	167)	/	17570.4
	=	0.16

Aarti Pharmalabs (BOM:543748) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Aarti Pharmalabs Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Aarti Pharmalabs's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Aarti Pharmalabs (BOM:543748) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aarti Pharmalabs Ltd (BOM:543748) » Definitions » Debt-to-Equity

Traded in Other Exchanges

AARTIPHARM:India

Address

204, Udyog Kshetra, Mulund Goregaon Link Road, 2nd floor,, Mulund West, Mumbai, MH, IND, 400080

Website

https://www.aartipharmalabs.com

Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. It manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, New Chemical Entities (NCE), and xanthine derivatives.

Aarti Pharmalabs (BOM:543748) Headlines

No Headlines